Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD

Image Source: Unsplash

An Introduction

The 10 clinical-stage AI-focused (designated with *) and psychedelic compound-based (designated with **) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD in July after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
 

The munKNEE Clinical-Stage BioTech Drug Stocks Portfolio

Below are the stock performances of the 10 constituents in the Portfolio last week, MTD and YTD, a description of their areas of focus, current market capitalizations and the latest news, analyses and commentary where pertinent:

1. *Relay Therapeutics (RLAY): UP 29.6% last week; UP 26.4% MTD; DOWN 25.2% YTD
   • Area of Focus: specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
   • Market Capitalization: $1090M
   • Latest News, Analyses and Commentary: None
2. *Absci Corporation (ABSI): UP 27.1% last week; UP 30.8% MTD; DOWN 4.0% YTD
   • Area of Focus: focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
   • Market Capitalization: $456M
   • Latest News, Analyses and Commentary: None
3. **atai Life Sciences (ATAI): UP 21.3% last week; UP 15.8% MTD; UP 9.2% YTD
   • Area of Focus: focuses on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Market Capitalization: $258M
   • Latest News, Analyses and Commentary: 
     •   atai Exploring Psychedelic Frontiers
4. *AbCellera Biologics (ABCL); UP 16.0% last week; UP 5.4% MTD; DOWN 45.4% YTD
   • Area of Focus: develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
   • Market Capitalization: $917M
   • Latest News, Analyses and Commentary:
     • AbCellera Biologics Upgraded to Buy: Here's What You Should Know
5. *Recursion Pharmaceuticals (RXRX): UP 14.2% last week; UP 11.5% MTD; DOWN 15.2% YTD
   • Area of Focus: has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
   • Market Capitalization: $2,240M
   • Latest News, Analyses and Commentary:
     • Is Recursion Pharmaceuticals Stock a Buy?
6. **Compass Pathways (CMPS): UP 12.4% last week; UP 15.4% MTD; DOWN 20.3% YTD
   • Area of Focus: focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Market Capitalization: $477M
   • Latest News, Analyses and Commentary:
     • Next-Gen Drug Company Compass Exploring Psychedelic Frontiers
7. *Schrödinger (SDGR): UP 8.2% last week; UP 15.8% MTD; DOWN 37.4% YTD
   • Area of Focus: specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
   • Market Capitalization: $1,630M
   • Latest News, Analyses and Commentary:
     • Gene Editing Stock Schrödinger Actually Making Money
8. **Mind Medicine (MNMD): UP 5.4% last week; UP 3.5% MTD; DOWN 13.9% YTD
   • Area of Focus: focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
   • Market Capitalization: $536M
   • Latest News, Analyses and Commentary:
     • MindMed to be Included in Russell 2000® and Russell 3000® Indexes
9.  **GH Research (GHRS): UP 2.0% last week; UP 2.8% MTD; UP 106.7% YTD
   • Area of Focus: focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
   • Market Capitalization: $624M
   • Latest News, Analyses and Commentary:
     • 3 Psychedelic Stocks to Ride to the Moon and Beyond
10. *Exscientia (EXAI): DOWN 1.0% last week; UP 11.6% MTD; DOWN 11.2% YTD
    • Area of Focus: reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
    • Market Capitalization: $639M
    • Latest News, Analyses and Commentary:
      • Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

Summary

On average,

• the above 10 stocks were UP 10.4% last week, UP 12.8% MTD and are now UP 13.8% YTD,
• the 4 constituents in the Psychedelic Compound-based Drug Stocks Portfolio (averaging $474M in market capitalization) were UP 6.8% last week, UP 6.6% MTD and are now UP 42.5% YTD while
• the 6 constituents in the AI-focused Drug Discovery Stocks Portfolio (averaging $1,175M in market cap) were UP 12.7% last week, UP 16.5% MTD but remain DOWN 29.0% YTD.

---

More By This Author:

Canadian Cannabis LPs Doubled Performance Of American MSOs This Week
All But 1 Of 6 Semiconductor Segments Outperformed The Nasdaq This Week
A Comparative Analysis Of The 12 Largest Cannabis Companies Puts Green Thumb #1